BAXFENDY
Jun 01, 2026
AstraZeneca’s BAXFENDY Enters the Hypertension Market: Can Aldosterone Synthase Inhibition Outperform Existing Therapies?
Summary In May 2026, the FDA approved AstraZeneca's BAXFENDY (baxdrostat), the world's first aldosterone synthase inhibitor (ASI), marking the arrival of an entirely new pharmacological class for a condition that affects 1.4 billion people globally. The approval addresses a stubborn clinical gap. Despite exi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
